Bli medlem
Bli medlem

Du är här


BioStock: SynAct comments on the revision of nephrology study

In July, SynAct Pharma applied for an amendment of the ongoing phase IIa study with AP1189 in patients with idiopathic membranous nephropathy (iMN). In the new study format, the dosing duration is increased from four weeks to three months and the new AP1189 tablet is used. The protocol amendment has now been approved by the Danish Medicines Agency and is currently being assessed in Sweden and Norwary. BioStock talked to CSO Thomas Jonassen.

Read the full article at

This is a press release from BioStock - Connecting Innovation & Capital.

Författare Cision